Abstract
Extensive evidence supports oxidative stress (OS) via endogenous and exogenous agents as an important factor in induction of autoimmunity. OS arises from the immune system and other endogenous sources. The literature contains support for OS involvement of various drugs and other exogenous substances that produce the condition. Studies reveal prevention or amelioration by antioxidants.
Keywords: systemic lupus erythematosus, autoimmunity, xenobiotics, oxidative stress, antioxidants.
Mini-Reviews in Medicinal Chemistry
Title: Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress
Volume: 3 Issue: 6
Author(s): Peter Kovacic and Jason D. Jacintho
Affiliation:
Keywords: systemic lupus erythematosus, autoimmunity, xenobiotics, oxidative stress, antioxidants.
Abstract: Extensive evidence supports oxidative stress (OS) via endogenous and exogenous agents as an important factor in induction of autoimmunity. OS arises from the immune system and other endogenous sources. The literature contains support for OS involvement of various drugs and other exogenous substances that produce the condition. Studies reveal prevention or amelioration by antioxidants.
Export Options
About this article
Cite this article as:
Kovacic Peter and Jacintho D. Jason, Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress, Mini-Reviews in Medicinal Chemistry 2003; 3 (6) . https://dx.doi.org/10.2174/1389557033487926
DOI https://dx.doi.org/10.2174/1389557033487926 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Spots, Blots, Peaks and Chips: Proteomic Approaches in Autoimmune Diseases
Current Pharmaceutical Design Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls
Current Topics in Medicinal Chemistry Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Current Pharmaceutical Design Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents